Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.

Cell reports. Medicine - 21 May 2024

van Eijck Casper W F, Real Francisco X, Malats Núria, Vadgama Disha, van den Bosch Thierry P P, Doukas Michail, van Eijck Casper H J, Mustafa Dana A M

Abstract excerpt

This study underscores GATA6's role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation. In a prospective treatment-naive cohort of patients with resected PDAC, GATA6 IHC proves a prognostic discriminator, associating high GATA6 expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GATA6 Transcription Factor

Share to Macrophages

Share to Neoadjuvant Therapy

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 38733987
DOI: 10.1016/j.xcrm.2024.101557
PMCID: PMC11148804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.PMID 38733987Read ↗

GATA6: A Pan-Cancer Transcription-Factor Biomarker Linking Diagnosis, Prognosis, and Anti- Tumour ImmunitySemantic proximity Read ↗

GATA6 in pancreatic cancer initiation and progressionSemantic proximity Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancerSemantic proximity Read ↗

Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancerSemantic proximity Read ↗

The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic AdenocarcinomaSemantic proximity Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Profiles and clinical significance of immune cell infiltration in pancreatic adenocarcinomaSemantic proximity Read ↗

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypesSemantic proximity Read ↗

Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.